WHWK
Whitehawk Therapeutics Inc·Healthcare
4.11
2.837%(−0.12)
Market ClosedLast Updated: — ET
52W L: $1.3952W H: $4.48
WHWK NEWS
prnewswire.com
2d ago
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
MORRISTOWN, N.J., April 16, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the Jones Trading Post-AACR Fireside Chat Series on Thursday, April 23, 2026, at 3 PM ET.
defenseworld.net
3d ago
Bryan Ball Sells 6,596 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) insider Bryan Ball sold 6,596 shares of the business's stock in a transaction on Friday, April 10th. The stock was sold at an average price of $3.43, for a total value of $22,624.28. Following the transaction, the insider owned 515,955 shares in the company, valued at approximately
defenseworld.net
3d ago
Bryan Ball Sells 50,000 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) insider Bryan Ball sold 50,000 shares of the company's stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $3.57, for a total value of $178,500.00. Following the sale, the insider owned 522,551 shares in the company, valued at $1,865,507.07.
prnewswire.com
Apr 10
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets MUC16 is highly and stably expressed in the most aggressive and most common subtypes of endometrial cancer Findings support Whitehawk's development of MUC16-directed ADC, HWK-016, currently being explored in Phase 1 for advanced ovarian and endometrial cancers MORRISTOWN, N.J., April 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today presented three posters from a real-world analysis supporting the therapeutic potential of targeting mucin 16 (MUC16) with a next-generation ADC for the treatment of ovarian and endometrial cancers at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women's Cancer, being held April 10-13, 2026, in San Juan, Puerto Rico.
defenseworld.net
Apr 5
David James Lennon Sells 26,858 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) CEO David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.48, for a total value of $93,465.84. Following the sale, the chief executive officer directly owned 793,549 shares
prnewswire.com
Mar 17
Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
MORRISTOWN, N.J., March 17, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it will present three preclinical abstracts, including an oral minisymposium and two posters, highlighting its next-generation antibody-drug conjugate (ADC) portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA.
